STERIS Cash & Equivalents increased by 32.7% to $423.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 173.0%, from $155.20M to $423.70M. Over 4 years (FY 2021 to FY 2025), Cash & Equivalents shows a downward trend with a -6.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
A universal metric for assessing a company's immediate financial health.
cash_and_equivalents| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $534.77M | $383.49M | $359.09M | $348.32M | $316.33M | $258.26M | $259.37M | $208.36M | $208.61M | $213.76M | $195.59M | $207.00M | $198.30M | $172.20M | $155.20M | $171.70M | $279.70M | $319.20M | $423.70M |
| QoQ Change | — | -28.3% | -6.4% | -3.0% | -9.2% | -18.4% | +0.4% | -19.7% | +0.1% | +2.5% | -8.5% | +5.8% | -4.2% | -13.2% | -9.9% | +10.6% | +62.9% | +14.1% | +32.7% |
| YoY Change | — | — | — | — | -40.8% | -32.7% | -27.8% | -40.2% | -34.1% | -17.2% | -24.6% | -0.7% | -4.9% | -19.4% | -20.6% | -17.1% | +41.0% | +85.4% | +173.0% |